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Abstract Using surface enhanced Raman spectroscopy (SERS)
which enables us to specifically detect traces of monomeric
amphotericin B (AmB), we were able to show that in a 1035 M
AmB suspension, the concentration of free drug was below 1038
M in the presence of low density lipoproteins (LDL) or plasma.
The affinity constant of AmB for LDL determined from
electronic absorption data, was found to be 4U106 M31.
Therefore, since AmB appears to be in the majority bound to
lipoproteins under in vivo conditions, its toxicity should not result
from the induction of host-cell transmembrane permeability but
rather from the internalization of the AmB-LDL complex.
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1. Introduction
Amphotericin B (AmB) is the drug of choice for many
serious systemic fungal infections, which owing to AIDS
and improved organ transplant immunosuppression drugs
are becoming tragically frequent in immune-compromised in-
dividuals [1]. Unfortunately severe side-e¡ects negate its use-
fulness and justify the numerous current studies aiming at
increasing its therapeutic index. As far as the molecular mech-
anism of action of this drug is concerned, it has often been
admitted that AmB binds to sterol-containing membranes and
forms transmembrane pores through which components es-
sential for the life of cells leak. The formation of these pores
has been widely ascertained in serum-free media or in red
blood cells, which are devoid of low density lipoprotein
(LDL) receptors. However, AmB binds to serum proteins, in
particular to LDL [2^4], which may a¡ect its mechanism of
action. Therefore, the following questions arise: whether the
a⁄nity of AmB for proteins is higher than that for cells and
whether it is the AmB-protein complex which is active, or
whether there is an exchange of the antibiotic between pro-
teins and membrane; and whether the complex AmB-LDL is
internalized by the LDL receptors of mammalian cells. Recent
studies have shown that this latter possibility may occur [5]
and that consequently, AmB is found in endosomes [6]. As a
result, the undesirable toxicity of AmB for host cells may take
its origin from a blockade of the endosome-lysosome fusion
and not from transmembrane permeability changes.
Strategies for decreasing AmB toxicity and improving its
therapeutic index, depend strongly on which of these mecha-
nisms is operative in vivo, i.e. transmembrane permeability
inducement or internalization of the AmB-LDL complex. Es-
timation of the amount of free, protein-bound and cell-bound
AmB, in plasma would allow us to draw conclusions. Un-
fortunately, in vivo, HPLC or bioassays, currently used to
determine the total AmB concentration in plasma, do not
provide this essential information. One study has, however,
shown that in the blood of rats treated with AmB, 80% of
the amphotericin B is bound to plasma proteins [4]. In vitro,
several studies have also shown that AmB binds to lipopro-
teins. The distribution of the drug among the di¡erent lip-
oproteins was also analyzed in detail [2^4]. Unfortunately,
the procedure used did not allow a clear estimation of free
AmB, the amount of which, above or below ca. 1 WM, would
or would not allow host-cell membrane permeabilization.
Spectroscopic studies (UV-visible absorption, circular dichro-
ism) should do it but the characteristic bands of bound AmB
and free AmB overlap partially. Under these conditions,
traces of free AmB are di⁄cult to detect. A recently developed
method, surface enhanced Raman spectroscopy (SERS) could
overcome this di⁄culty since it enables us to detect traces of
organic molecules. A SERS e¡ect can be observed provided
that the molecules under study are adsorbed on a rough sur-
face of certain metals such as silver, gold or copper. Silver,
roughened electrodes and aggregated colloids are easily pre-
pared and are the most used SERS active substrates. The very
large intensity enhancement of the Raman spectrum mainly
arises from the excitation, within the surface plasmon band of
the rough silver, with the usual laser lines either in the green
(514.5 nm), in the red (632.5 nm) or even in the near infrared
(1064 nm). We have previously shown [7] that in silver col-
loids prepared according to the procedure of Creighton et al.
[8], resonant SERS (SERRS) e¡ect us allows to speci¢cally
detect monomeric AmB at very low concentrations (ca.
10310 M), which is about 1000 times lower than those detect-
able by UV-visible absorption spectroscopy. The presence of
AmB aggregates in the vicinity of the silver surface only man-
ifests by a perturbing e¡ect on the whole intensity SERRS
spectra. For this reason we thought that it would be a good
method to detect, or not, traces of free AmB in the presence
of LDL.
2. Materials and methods
2.1. Materials
The silver colloids were prepared according to Creighton et al. [8],
by reducing silver nitrate with an excess of NaBH4 at room temper-
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ature. Solutions were mixed slowly, then vigorously stirred for 45^60
min.
AmB was a gift from Squibb (France) and used without further
puri¢cation.
Low density lipoproteins from human plasma were purchased from
Sigma. The initial solution at a 5 mg/ml protein concentration was
dialysed against phosphate bu¡er saline (155 mM NaCl, 7 mM
Na2HPO4, 3 mM KH2PO4, adjusted to pH 7.4) in order to remove
EDTA and proteins of molecular mass lower than 12 000 Da. The
addition of the LDL solutions to the colloid suspension brings chlo-
ride anions, at a maximum ¢nal concentration of less than 2 mM,
which has been shown not to signi¢cantly a¡ect SERRS signals.
Plasma was separated from EDTA-treated blood (1 mg/ml) ob-
tained from normal fasting donors, by two centrifugations at
3000Ug for 5 min.
2.2. Spectroscopy measurements
The interaction of AmB with LDL was measured using a 1033 M
stock solution of AmB in DMSO and a 1 mg/ml protein stock sol-
ution of LDL in PBS. To 0.5 ml of water was added an aliquot of
LDL solution in order to obtain the desired ¢nal concentration. Then,
20 Wl of the AmB stock solution was added to water in order to
obtain a 1 ml ¢nal volume. The mixture was incubated for 15 min
at room temperature. Then this solution was diluted in 1 ml of water
for absorption measurements or 1 ml of silver colloids preferably
aggregated by 60 mM NaNO3 for SERS studies. Spectra were imme-
diately recorded. The presence of NaNO3 induces changes in the size
and shape of the metal particles, leading to a further increase of the
SERS intensity of AmB adsorbed on the metal surface [9].
UV-visible absorption spectra were recorded on a Varian Cary 219
spectrophotometer, CD spectra on a Jobin-Yvon Mark V dichro-
graph.
SERS spectra were excited at two excitation wavelengths: the 514.5
nm line of a Spectra Physics ionized Argon laser (power 50 mW)
which allowed excitation in resonance conditions, and the 1064 nm
line of an YAG-Nd IR laser (power 200 mW) which was out of
resonance. In the ¢rst case spectra were recorded on a multichannel
Dilor XY modular spectrophotometer equipped with an intensi¢ed
1024-diode-array detector cooled by the Peltier e¡ect; in the second
case a Perkin-Elmer system 2000 NIR FT Raman spectrophotometer
was used.
3. Results
3.1. UV-visible absorption and circular dichroism
AmB in an aqueous solution is present under monomeric
and self-associated forms. UV-visible absorption and circular
dichroism allow us to speci¢cally detect them: a band at 409
nm is a speci¢c of monomeric AmB, a band at 340 nm (a
doublet for circular dichroism) is a speci¢c of the aggregated
form [10]. The addition of increasing concentrations of LDL
to the 1035 M AmB solution resulted in a change of the
absorption spectra of AmB (Fig. 1). In the 400^430 nm re-
gion, the 409 nm band decreased, while a new band appeared
at 415 nm. Its intensity increased up to an optical density of
0.47 (with a 1 cm cell path length), reached for a LDL con-
centration of 0.05 mg/ml in protein. In the 340 nm region, the
absorption band decreased, as did the dichroic doublet [2].
The time dependence of the appearance of the band at 415
nm was also recorded for a mixture of 1035 M AmB and 0.05
mg/ml of LDL. The time needed for reaching 50% of its
maximum intensity was similar to that needed for the disap-
pearance of 50% of the band intensity centered at 340 nm
(data not shown).
Assuming that the new 415 nm band re£ects the AmB
bound to LDL, we used the already described algorithm
[10] which enables us to quantify, from the absorption inten-
sities at 409, 420 and 415 nm, the di¡erent forms of AmB, i.e.
monomeric, self-associated and bound forms. From the con-
centrations of free AmB, a Scatchard plot was drawn as
shown in Fig. 2, assuming that cholesterol is the binding
site [2]. An association constant of K=4U106 M31, with a
stoichiometry of 1 molecule of amphotericin B for three mol-
ecules of cholesterol, was determined.
3.2. SERRS spectra
As previously described [7], the SERRS spectra of AmB
consists essentially in two main lines at ca. 1556 and 1153
cm31. For increasing concentrations of LDL or plasma, a
rapid intensity decrease of these Raman lines was observed.
In order to quantify this e¡ect, the ratio of the intensities of
the 1556 cm31 line and the 680 cm31 line of DMSO was
measured. As the amount of DMSO was maintained constant
in all experiments (5% v/v) and this solvent does not give rise
to a SERS spectrum under these conditions, the intensity of
the line at 680 cm31 can be used as an internal reference.
Two excitation wavelengths were used for these measure-
ments. The excitation at 514.5 nm close to an electronic ab-
sorption band of AmB, allowed us to match the Raman res-
onance conditions with the concomitant strong enhancement
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Fig. 1. Absorption spectra of 1035 M AmB solutions in water in
presence of LDL at various concentrations: (thick line) 0, (thin line)
0.003 and (dotted line) 0.05 mg/ml.
Fig. 2. Scatchard plot of the interaction of AmB with LDL:
r/L = K(n3r) with r = [AmB]bound/[cholesterol] and L = [AmB]free.
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in SERS intensities (SERRS e¡ect), whereas with the 1064 nm
excitation, o¡ resonance SERS spectra were obtained. The
intensity ratios, measured at 514.5 nm excitation are shown
in Fig. 3; it should be noted that they rapidly decrease from
ca. 20 to 2, at a LDL concentration of 0.01 mg/ml in protein
and they remain almost constant up to 0.05 mg/ml. Similar
behavior was obtained for the intensity ratios measured with
the 1064 nm excitation, but the measurements were less pre-
cise due to the poorest signal to noise ratios of SERS spectra
excited at this wavelength (data not shown). However, this
latter result gives evidence that no photochemical e¡ect per-
turbed the measured ratios obtained under resonance condi-
tions at 514.5 nm. A similar decrease was also observed with
increasing plasma concentrations, but in this case SERS spec-
tra could only be excited with a 1064 nm excitation wave-
length since at 514.5 nm excitation wavelength spectra were
obscured by a strong £uorescence background.
The intensity ratio of the 1556 and 680 cm31 lines was
measured for increasing concentrations of AmB alone, from
1038 to 1034 M with the 514.5 nm excitation wavelength (Fig.
4). From the comparison between this plot and that obtained
in the presence of LDL (Fig. 3), it was possible to estimate the
concentration of free AmB in solution, in the presence of
LDL, assuming as it was stated previously [7] that the
AmB-LDL complex is not SERS active. These data are pre-
sented in Fig. 5 for di¡erent concentrations of LDL; it clearly
appears that from 0.02 mg/ml of LDL and up to 0.05 mg/ml
the amount of free AmB is ca. 1038 M.
4. Discussion
The most striking result of this study is that in the presence
of LDL at a concentration higher than 0.02 mg/ml in protein,
and 1035 M total AmB, after a 15 min incubation, the con-
centration of free monomeric AmB detected by SERS was
very low, signi¢cantly lower than 1038 M. In blood, the
LDL concentration being higher, the amount of bound
AmB should also be higher and consequently the free AmB
is negligible in these conditions (6 1038 M). Furthermore, in
serum at 25‡C, the amount of bound AmB is identical in LDL
and HDL (high density lipoprotein) fractions [3], higher in
VLDL and in non-lipoprotein fractions [4]. Under these con-
ditions, it can be said that at the concentration of total AmB
found in the sera of Fungizone-treated patients, that is around
5U1036 M, the amount of free monomeric AmB in the blood
is negligible. Therefore, under these conditions the formation
of transmembrane channels is unlikely to occur.
It is interesting to compare the a⁄nity constant of AmB for
LDL obtained in this study from absorption data (4U106
M31) with that obtained previously from circular dichroism
measurements [2] (4U105 M31). To explain this di¡erence, it
should be recalled that absorption mainly detects the mono-
meric form of AmB whereas circular dichroism detects self-
associated species. Thus, the a⁄nity of monomeric AmB for
LDL would appear 10-fold higher than that of self-associated
AmB (although the stoichiometry of the association is com-
parable, about three cholesterol molecules for one amphoter-
icin B molecule). However, the self-associated species involve
water-soluble oligomers and non-water-soluble aggregates:
only water-soluble oligomers were shown to be toxic for hu-
man erythrocytes [11]. It may be assumed in the same way,
that the monomers and the water-soluble oligomers only, in-
teract with LDL and that the a⁄nity constant of AmB for
LDL is that obtained from absorption data. The absence of,
or the weak binding of the non-water-soluble aggregates re-
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Fig. 3. Relative intensity of SERRS lines at 1556 cm31 (AmB) and
680 cm31 (DMSO) as a function of LDL concentration (1035 M
AmB in the presence of colloidal silver). Laser excitation: 514.5
nm; 50 mW.
Fig. 4. Relative intensity SERRS lines at 1556 cm31 (AmB) and 680
cm31 (DMSO) as a function of AmB concentrations. Laser excita-
tion: 514.5 nm; 50 mW.
Fig. 5. Variation of the free AmB concentration in the presence of
increasing concentration of LDL, as deduced from Figs. 3 and 4.
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sults in a lowered global a⁄nity, as detected by circular di-
chroism.
Finally our results support the hypothesis that AmB toxic-
ity for host cells does not result from transmembrane perme-
abilization by the free drug but implies a binding of the drug
to LDL and LDL receptors. Thus, recent observations could
be explained: the toxicity of AmB/LDL for rabbits is higher
than that of AmB alone [12]; the inhibition of the AmB-lip-
oprotein interaction is correlated to the decrease of toxicity
for mice of AmB bound to surfactants [13]; the toxicity of
AmB for LLC PK1 renal cells is reduced when the cells do not
express LDL receptors [14].
In conclusion, the importance of the modulation in plasma
lipoprotein concentration and lipid composition upon the reg-
ulation of the activity of AmB should be emphasized [1,15].
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